Entering the US pharmaceutical market involves more than a single “FDA approval” milestone. Product type, application pathway, evidence package and manufacturing readiness shape the commercial timeline together.
What do NDA and ANDA mean?
A New Drug Application (NDA) is the pathway used to request marketing approval for a new drug supported by safety and effectiveness evidence. An Abbreviated New Drug Application (ANDA) is used for generic drugs and relies on a reference product.
The pathway is not only a regulatory decision. Market size, competitive intensity, the reference product, patents and exclusivities should also inform the commercial plan.
When should commercial readiness begin?
Commercial readiness should not be postponed until an FDA decision. Early work on positioning, pricing assumptions, channels, partners and launch capabilities can make investment choices clearer.
- Clarify the product and intended application pathway.
- Review the market through Orange Book and Drugs@FDA resources.
- Connect regulatory, manufacturing and commercial timelines.
- Confirm claims and target dates with qualified specialists.
Questions for the first assessment
Which patient and customer need does the product address? Which products shape the competitive and reference landscape? How does the application and manufacturing timeline affect launch? Which US capabilities should be internal and which require partners?
Answering these questions early prevents regulatory planning and commercial strategy from becoming disconnected.
Kaynaklar / Sources
- FDA — How Drugs are Developed and Approved
- FDA — Abbreviated New Drug Application (ANDA)
- FDA — Orange Book
This article is for general information and is not legal, regulatory or medical advice. Confirm product-specific requirements with qualified specialists and the relevant authorities.
